Lipoprotein glycation and its metabolic consequences

Current Opinion in Lipidology

Volumn 8, Issue 3, 1997, Pages 174-180

  Lyons, Timothy J ^a   Jenkins, Alicia J ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; CHYLOMICRON; FREE RADICAL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN;

AGING; ATHEROSCLEROSIS; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; GLYCATION; HEALTH STATUS; HUMAN; KIDNEY DISEASE; LIPOPROTEIN METABOLISM; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

ANIMALS; DIABETIC ANGIOPATHIES; GLYCOSYLATION; HUMANS; LIPOPROTEIN(A); LIPOPROTEINS; LIPOPROTEINS, LDL; MODELS, BIOLOGICAL; REACTIVE OXYGEN SPECIES;

EID: 0030857847     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199706000-00008     Document Type: Review

References (69)

1. Baynes JW: Role of oxidative stress in development of complications in diabetes. Diabetes 1991, 40:405-412.
2. ε-(carboxymethyl)lysine (CML), is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996, 271:9982-9826. This paper demonstrated that N′-(carboxymethyl)lysine, one of the few identified products of combined glycation and oxidation of proteins and a potentially important epitope in antibody formation, may also be formed from glyoxal derived from metal-catalysed oxidation of polyunsaturated fatty acids. N′-(carboxymethyl)lysine is therefore both a glycoxidation product and a lipoxidation product, and may therefore be a more general marker of oxidative stress than was originally believed.
3. Requena JR, Fu M-X, Ahmed MU, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR: Quantitation of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human LDL. Biochem J 1997, 322:317-325.
4. Requena JR, Fu M-X, Ahmed MU, Jenkins AJ, Lyons TJ, Thorpe SR: Lipoxidation products as biomarkers of oxidative damage to proteins during lipid peroxidation reactions. Nephrol Dialysis Transplant 1996, 11(Suppl5):48-53.
5. Lyons TJ, Jenkins AJ: Glycation, oxidation and lipoxidation in the development of the complications of diabetes mellitus: a "carbonyl stress" hypothesis. Diabetes Rev 1997, (In press).
6. Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, Vlassara H: Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci U S A 1994, 91:9441-9445.
7. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H: Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A 1993, 90:6434-6438.
8. Curtiss LK, Witztum JL: Plasma apolipoproteins A1, AII, B, CI, and E are glucosylated in hyperglycemic diabetic subjects. Diabetes 1985, 34:452-461.
9. Kobayashi K, Ogasahara N, Sakoguchi T, Kimura M, Taniuchi K, Matsuoka A: Agarose gel electrophoresis with nitroblue tetrazollum coloration for determination of glycated lipoproteins in serum from diabetics. Clin Chem 1990, 36:65-69.
10. Yegin A, Özben T: Serum glycated lipoproteins in type II diabetic patients with and without complications. Ann Clin Biochem 1995, 32:459-463.
11. Yegin A, Özben T, Yegin H: Glycation of lipoproteins and accelerated atherosclerosis in non-insulin-dependent diabetes mellitus. Int J Clin Lab Res 1995, 25:157-161.
12. Mamo JCL, Szeto L, Steiner G: Glycation of very low density lipoprotein from rat plasma impairs its catabolism. Diabetologia 1990, 33:339-345.
13. Kobayashi K, Watanabe J, Umeda F, Nawata H: Glycation accelerates the oxidation of low density lipoprotein by copper ions. Endocrine Journal 1995, 42:461-465.
14. Thornalley PJ, Stern A: The production of free radicals during the autoxidation of monosaccharides by buffer ions. Carbohydr Res 1984, 134:191-204.
15. Thornalley PJ: Monosaccharide auto-oxidation in health and disease. Environ Health Perspect 1985, 64:297-307.
16. 2. Diabetes Metab Rev 1988, 14:25-30.
17. 2-radical generation by Maillard compounds. J Diab Complications 1988, 2:19-21.
18. Hunt JV, Dean RT, Wolff SP: Hydroxyl radical production and autoxidative glycosylation. Biochem J 1988, 256:205-212.
19. Kawamura M, Heinecke JW, Chait A: Pathophysiologic concentrations of glucose promote oxidative modification by a superoxide-dependent pathway. J Clin Invest 1994, 94:771-778.
20. Bellomo G, Maggi E, Ploi M, Agosta FG, Bollati P, Finardi G: Autoantibodies against oxidatively modified low density lipoproteins in NIDDM. Diabetes 1995, 44:60-66.
21. Lyons TJ, Li W, Wells-Knecht MC, Jokl R: Toxicity of mildly modified low density lipoproteins to cultured retinal capillary endothelial cells and pericytes. Diabetes 1994, 43:1090-1095.
22. Wolff SP, Dean RT: Glucose autoxidation and protein modification: the potential role of "autoxidative glycosylation" in diabetes mellitus. Biochem J 1987, 245:243-250.
23. Mullarkey CJ, Edelstein D, Brownlee M: Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun 1990, 173:932-939.
24. Bowie A, Owens D, Collins P, Johnson A, Tomkin G: Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient? Atherosclerosis 1993, 102:63-67.
25. Tsai EC, Hirsch IB, Brunzell JD, Chait A: Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 1994, 43:1010-1014.
26. Chait A, Brazg RL, Tribble DL, Krauss RM: Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993, 94:350-356.
27. Stringer MD, Gorog PG, Freeman A, Kakkar VV: Lipid peroxides and atherosclerosis. BMJ 1989, 298:281-284.
28. Jenkins AJ, Klein RL, Chassereau CN, Hermeyer KL, Lopes-Virella MF: LDL from patients with well-controlled IDDM is not more susceptible to in vitro oxidation. Diabetes 1996, 45:762-767. This paper is consistent with the possibility that increased oxidizability of LDL occurs in diabetes only if there is severe hyperglycemia, or if vascular complications are already present.
29. Lyons TJ: Glycation of low density lipoprotein and its metabolic consequences. Diabetes 1992, 41(Suppl 2):67-73.
30. Lopes-Virella M, Virella G: Cytokines, modified lipoproteins, and arteriosclerosis in diabetes. Diabetes 1996, 45:S40-S44. A broad, excellent review.
31. Tames FJ, Mackness MI, Arrol S, Laing I, Durrington PN: Non-enzymatic glycation of apolipoprotein B in the sera of diabetic and non-diabetic subjects. Atherosclerosis 1992, 93:237-244.
32. Gupta S, Rifici V, Crowley S, Brownlee M, Shan Z, Schlondorff D: Interactions of LDL and modified LDL with mesangial cells and matrix. Kidney Int 1992, 41:1161-1169.
33. Bucala R, Mitchell R, Arnold K, Innerarity T, Vlassara H, Cerami A: Identification of the major site of apolipoprotein B modification by advanced glycation end products blocking uptake by the low density lipoprotein receptor. J Biol Chem 1995, 270:10828-10832.
34. Gugliucci A, Bendayan: Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 1996, 39:149-160.
35. Watanabe J, Wohltmann HJ, Klein RL, Colwell JA, Lopes-Virella MF: Enhancement of platelet aggregation by low-density lipoproteins from IDDM patients. Diabetes 1988, 37:1652-1657.
36. Lyons TJ, Klein RL, Baynes JW, Stevenson HC, Lopes-Virella MF: Stimulation of cholesteryl ester synthesis in human monocyte-derived macrophages by low-density lipoproteins from type I (insulin-dependent) diabetic patients: the influence of non-enzymatic glycosylation of low-density lipoproteins. Diabetologia 1987, 30:916-923.
37. Lopes-Virella MF, Klein RL, Lyons TJ, Stevenson HC, Witztum JL: Glycosylation of low-density lipoprotein enhances cholesteryl ester synthesis in human monocytes-derived macrophages. Diabetes 1988, 37:550-557.
38. Brownlee M, Vlassara H, Cerami A: Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein. Diabetes 1985, 34:938-941.
39. Lyons TJ, Baynes JW, Patrick JS, Colwell JA, Lopes-Virella MF: Glycosylation of low density lipoprotein in patients with Type I (insulin-dependent) diabetes: correlations with other parameters of glycaemic control. Diabetologia 1986, 29:685-689.
40. Jack CM, Sheridan B, Kennedy L, Stout RW: Non-enzymatic glycosylation of low-density lipoprotein. Results of an affinity chromatography method. Diabetologia 1988, 31:126-128.
41. Klein RL, Laimans M, Lopes-Virella MF: Isolation, characterization and metabolism of the glycated and non-glycated sub-fractions of low density lipoproteins isolated from type 1 diabetic patients and non-diabetic subjects. Diabetes 1995, 44:1093-98. Two subfractions of LDL present in vivo were separated by affinity chromatography. The technique allows isolation of the more modified LDL present in plasma, allowing the effects of modification to be more easily identified. The percentage of total LDL in the glycated subfraction was fourfold increased in diabetic patients. Irrespective of origin, the glycated subfraction exhibited triglyceride enrichment, and more atherogenic interactions with cells (fibroblasts and macrophages).
42. Kortlandt W, Benschop C, Erkelens DW, Thijssen JHH: A simple method for the measurement of total and glycated apolipoprotein B and its relevance to apolipoprotein B metabolism in diabetes mellitus. Clin Chim Acta 1989, 186:109-118.
43. Panteghini M, Bonora R, Pagani F: Determination of glycated apolipoprotein B in serum by a combination of affinity chromatography and immunonephelometry. Ann Clin Biochem 1994, 31:544-549.
44. Panteghini M, Cimino A, Pagani F, Girelli A: Nonenzymic glycation of apolipoprotein B in patients with insulin- and noninsulin-dependent diabetes mellitus. Clin Biochem 1995, 28:587-592.
45. Klein RL, Lyons TJ, Lopes-Virella MF: Metabolism of very low- and low-density lipoproteins isolated from normolipidaemic Type 2 (non-insulin-dependent) diabetic pateints by human monocyte-derived macrophages. Diabetologia 1990, 33:299-305.
46. Kobayashi J, Watanabe J, Umeda F, Masakado M, Ono Y, Taniguchi S, Yanase T, Hashimoto T, Sako Y, Hawata H: Metabolism of oxidized glycated low-density lipoprotein in cultured bovine aortic endothelial cells. Horm Metab Res 1995, 27:356-362.
47. Kobayashi K, Watanabe J, Umeda F, Taniguchi S, Masakado M, Yamauchi T, Nawata H: Enhancement of prostacyclin production in cultured bovine aortic endothelial cells by oxidized glycated low-density lipoprotein. Prostaglandins Leukot Essent Fatty Acids 1995, 52:263-270.
48. Sobenin IA, Tertov VV, Orekhov AN: Characterization of chemical composition of native and modified low density lipoprotein occurring in the blood of diabetic patients. Int Ang 1994, 13:78-83.
49. Cohen MP, Lautenslager G, Shea E: Glycated LDL concentrations in non-diabetic and diabetic subjects measured with monoclonal antibodies reactive with glycated apolipoprotein B epitopes. Eur J Clin Chem Clin Biochem 1993, 31:707-713.
50. Witztum JL, Fisher M, Pietro T, Steinbrecher UP, Elam RL: Nonenzymatic glucosylation of high-density lipoprotein accelerates its catabolism in guinea pigs. Diabetes 1982, 31:1029-1032.
51. Duell PB, Oram JF, Bierman EL: Nonenzymatic glycosylation of HDL resulting in inhibition of high-affinity binding to cultured human fibroblasts. Diabetes 1990, 39:1257-1263.
52. Duell PB, Oram JF, Bierman EL: Nonenzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux. Diabetes 1991, 40:377-384.
53. Berthezene F: Non-insulin dependent diabetes and reverse cholesterol transport. Atherosclerosis 1996, 124(Suppl):S39-S42.
54. Calvo C, Verdugo C: Association in vivo of glycated apolipoprotein A1 with high density lipoproteins. Eur J Clin Chem Clin Biochem 1992, 30:3-5.
55. Calvo C, Ulloa N, Pozo RD, Verdugo C: Decreased activation of lecithin: cholesterol acyltransferase by glycated apolipoprotein A-I. Eur J Clin Chem Clin Biochem 1993, 31:217-220.
56. Mackness M, Mackness B, Durrington PN, Connelly PW, Hegele RA: Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996, 7:69-76.
57. Rainwater DL, MacCluer JW, Stern MP, VandeBerg JL, Haffner SM: Effects of NIDDM on lipoprotein(a) concentration and apolipoprotein(a) size. Diabetes 1994, 43:942-946.
58. 100 rather than apo(a).
59. 100, presumably because of the low lysine content of apo(a). Lp(a) glycation affected its binding to heparin sepharose, and its interactions with human macrophages.
60. Lyons TJ, Bailie K, Dunn JA, Dyer DG, Thorpe SR, Baynes JW: Decrease in skin collagen glycosylation with improved glycemic control in patients with insulin-dependent diabetes mellitus. J Clin Invest 1991, 87:1910-1915.
61. Reaven P, Parthasarathy S, Grasse BJ, Miller E, Steinberg D, Witztum JL: Effects of oleate-rich and linoleate-rich diets on the susceptibility of low density lipoprotein to oxidative modification in mildly hypercholesterolemic subjects. J Clin Invest 1993, 91:668-676.
62. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willet WC: Vitamin E consumption and the risk of coronary artery disease in women. N Engl J Med 1993, 328:1444-1449.
63. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willet WC: Vitamin E consumption and the risk of coronary artery disease in men. N Engl J Med 1993, 328:1450-1456.
64. Gey KF, Puska P: Plasma vitamins E and A inversely correlated to mortality from ischemic heart disease in cross-cultural epidemiology. Ann N Y Acad Sci 1989, 570:268-282.
65. Heaven PD, Herold DA, Barnett J, Edelman S: Effects of vitamin E on susceptibility of low-density lipoprotein and low-density lipoprotein subfractions to oxidation and on protein glycation in NIDDM. Diabetes Care 1995, 18:807-816.
66. Fuller CJ, Chandalia M, Garg A, Grundy SM, Jialal I: RRR-α-tocopheryl acetate supplementation at pharmacologie doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus. Am J Clin Nutr 1996, 63:753-759.
67. Jenkins A, Li W, Ma JX, Willingham M, Lyons T: Effect of α-tocopherol supplementation on development of toxicity of modified LDL towards retinal capillary cells. Diabetes 1996, 45(Suppl 2):16A.
68. Lyons TJ, Li W: Aminoguanidine and the cytotoxicity of modified LDL to retinal capillary endothelial cells. Diabetes 1994, 43(Suppl 1):112A.
69. Vasan S, Zhang X, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, Basgen J, Wagle D, Shih D et al.: An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 1996, 382:275-278. This exciting paper describes a compound, N-phenacylthiazolium bromide, capable of cleaving AGE-derived protein crosslinks under physiologic conditions. Vulnerable cross-links are those derived from α-dicarbonyl intermediates.